Role of anti-MHC class I antibody in facilitating transplant accommodation

Critical Reviews in Immunology

Volumn 28, Issue 6, 2008, Pages 485-511

  Atz, Mary E ^a   Reed, Elaine F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Accommodation; Cell survival; Endothelial cell; MHC class I; Transplantation

Indexed keywords

ANTIBODY; CD59 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C4D; FIBROBLAST GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERLEUKIN 13; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PAXILLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN 14 3 3; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN KINASE FYN; PROTEIN TYROSINE KINASE; S6 KINASE; UNINDEXED DRUG;

ACUTE ANTIBODY MEDIATED REJECTION; ACUTE GRAFT REJECTION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CHRONIC ANTIBODY MEDIATED REJECTION; CHRONIC GRAFT REJECTION; COMPLEMENT ACTIVATION; ENDOTHELIUM CELL; GRAFT SURVIVAL; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNE RESPONSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 62449228012     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevimmunol.v28.i6.20     Document Type: Review

References (165)

1. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation. 2008;86(3):377-83.
2. King KE, Warren DS, Samaniego-Picota M, Campbell-Lee S, Montgomery RA, Baldwin WM III. Antibody, complement and accommodation in ABO-incompatible transplants. Curr Opin Immunol. 2004;16(5):545-9.
3. Koch CA, Khalpey ZI, Platt JL. Accommodation: preventing injury in transplantation and disease. J Immunol. 2004;172(9):5143-8.
4. Tang AH, Platt JL. Accommodation of grafts: implications for health and disease. Hum Immunol. 2007;68(8):645-51.
5. Soares MP, Lin Y, Sato K, Stuhlmeier KM, Bach FH. Accommodation. Immunol Today. 1999;20(10):434-7.
6. Williams JM, Holzknecht ZE, Plummer TB, Lin SS, Brunn GJ, Platt JL. Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. Transplantation. 2004;78(10):1471-8.
7. Chopek MW, Simmons RL, Platt JL. ABO-incompatible kidney transplantation: initial immunopathologic evaluation. Transplant Proc. 1987;19(6):4553-7.
8. Platt JL, Vercellotti GM, Dalmasso AP, Matas AJ, Bolman RM, Najarian JS, Bach FH. Transplantation of discordant xenografts: a review of progress. Immunol Today. 1990;11(12):450-6; discussion 456-7.
9. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol. 2007;18(4):1046-56.
10. Bach FH, Hancock WW, Ferran C. Protective genes expressed in endothelial cells: a regulatory response to injury. Immunol Today. 1997;18(10):483-6.
11. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol. 2005;5(10):807-17.
12. Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens. 2002;11(6):609-18.
13. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum Immunol. 2008;69(10):591-604.
14. Shimizu A, Colvin RB. Pathological features of antibody-mediated rejection. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5(3):199-214.
15. Joosten SA, van Kooten C, Paul LC. Pathogenesis of chronic allograft rejection. Transpl Int. 2003;16(3):137-45.
16. Sumitran-Holgersson S. Relevance of MICA and other non-HLA antibodies in clinical transplantation. Curr Opin Immunol. 2008;20(5):607-13.
17. Shimizu A, Yamada K, Sachs DH, Colvin RB. Persistent rejection of peritubular capillaries and tubules is associated with progressive interstitial fibrosis. Kidney Int. 2002;61(5):1867-79.
18. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13(3):806-16.
19. Jin YP, Jindra PT, Gong KW, Lepin EJ, Reed EF. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation. 2005;79(3 Suppl):S19-21.
20. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation. 1990;49(1):85-91.
21. Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation. 1992;53(3):550-5.
22. Wagner DD. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. Thromb Haemost. 1993;70(1):105-10.
23. Lowenstein CJ, Morrell CN, Yamakuchi M. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med. 2005;15(8):302-8.
24. Yamakuchi M, Kirkiles-Smith NC, Ferlito M, Cameron SJ, Bao C, Fox-Talbot K, Wasowska BA, Baldwin WM III, Pober JS, Lowenstein CJ. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A. 2007;104(4):1301-6.
25. Morrell CN, Murata K, Swaim AM, Mason E, Martin TV, Thompson LE, Ballard M, Fox-Talbot K, Wasowska B, Baldwin WM III. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res. 2008;102(7):777-85.
26. Kreis HA, Ponticelli C. Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. Transplantation. 2001;71(11 Suppl):S5-9.
27. Paul LC. Immunologic risk factors for chronic renal allograft dysfunction. Transplantation. 2001;71(11 Suppl):S17-23.
28. Paul LC, Fellstrom B. Chronic vascular rejection of the heart and the kidney - have rational treatment options emerged? Transplantation. 1992;53(6):1169-79.
29. Soleimani B, Lechler RI, Hornick PI, George AJ. Role of alloantibodies in the pathogenesis of graft arteriosclerosis in cardiac transplantation. Am J Transplant. 2006;6(8):1781-5.
30. Cherry R, Nielsen H, Reed E, Reemtsma K, Suciu-Foca N, Marboe CC. Vascular (humoral) rejection in human cardiac allograft biopsies: relation to circulating anti-HLA antibodies. J Heart Lung Transplant. 1992;11(1 Pt 1):24-9; discussion 30.
31. Davenport A, Younie ME, Parsons JE, Klouda PT. Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection. Nephrol Dial Transplant. 1994;9(9):1315-9.
32. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Transplantation. 1996;61(4):566-72.
33. Reed EF, Demetris AJ, Hammond E, Itescu S, Kobashigawa JA, Reinsmoen NL, Rodriguez ER, Rose M, Stewart S, Suciu-Foca N, Zeevi A, Fishbein MC. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25(2):153-9.
34. Hourmant M, Cesbron-Gautier A, Terasaki PI, Mizutani K, Moreau A, Meurette A, Dantal J, Giral M, Blancho G, Cantarovich D, Karam G, Follea G, Soulillou JP, Bignon JD. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol. 2005;16(9):2804-12.
35. Cai J, Terasaki PI. Post-transplantation antibody monitoring and HLA antibody epitope identification. Curr Opin Immunol. 2008;20(5):602-6.
36. Mauiyyedi S, Pelle PD, Saidman S, Collins AB, Pascual M, Tolkoff-Rubin NE, Williams WW, Cosimi AA, Schneeberger EE, Colvin RB. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol. 2001;12(3):574-82.
37. Smith RN, Brousaides N, Grazette L, Saidman S, Semigran M, Disalvo T, Madsen J, Dec GW, Perez-Atayde AR, Collins AB. C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant. 2005;24(9):1202-10.
38. Regele H, Bohmig GA, Habicht A, Gollowitzer D, Schillinger M, Rockenschaub S, Watschinger B, Kerjaschki D, Exner M. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol. 2002;13(9):2371-80.
39. Rodriguez ER, Skojec DV, Tan CD, Zachary AA, Kasper EK, Conte JV, Baldwin WM III. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant. 2005;5(11):2778-85.
40. Haas M, Segev DL, Racusen LC, Bagnasco SM, Locke JE, Warren DS, Simpkins CE, Lepley D, King KE, Kraus ES, Montgomery RA. C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts. J Am Soc Nephrol. 2009;20(1):197-204.
41. Jindra PT, Zhang X, Mulder A, Claas F, Veale J, Jin YP, Reed EF. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation. 2006;82(1 Suppl):S33-5.
42. Bian H, Harris PE, Reed EF. Ligation of HLA class I molecules on smooth muscle cells with anti-HLA antibodies induces tyrosine phosphorylation, fibroblast growth factor receptor expression and cell proliferation. Int Immunol. 1998;10(9):1315-23.
43. Bian H, Reed EF. Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFN-gamma and TNF-alpha. J Immunol. 1999;163(2):1010-8.
44. Harris PE, Bian H, Reed EF. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. J Immunol. 1997;159(11):5697-704.
45. Heemels MT, Ploegh H. Generation, translocation, and presentation of MHC class Irestricted peptides. Annu Rev Biochem. 1995;64:463-91.
46. Erlich HA, Opelz G, Hansen J. HLA DNA typing and transplantation. Immunity. 2001;14(4):347-56.
47. Peaper DR, Cresswell P. Regulation of MHC class I assembly and peptide binding. Annu Rev Cell Dev Biol. 2008;24:343-68.
48. Reed EF. Signal transduction via MHC class I molecules in endothelial and smooth muscle cells. Crit Rev Immunol. 2003;23(1-2):109-28.
49. Jindra PT, Jin YP, Rozengurt E, Reed EF. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol. 2008;180(4):2357-66.
50. Jin YP, Singh RP, Du ZY, Rajasekaran AK, Rozengurt E, Reed EF. Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J Immunol. 2002;168(11):5415-23.
51. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005;6(1):56-68.
52. Jin YP, Korin Y, Zhang X, Jindra PT, Rozengurt E, Reed EF. RNA interference elucidates the role of focal adhesion kinase in HLA class I-mediated focal adhesion complex formation and proliferation in human endothelial cells. J Immunol. 2007;178(12):7911-22.
53. Plopper GE, McNamee HP, Dike LE, Bojanowski K, Ingber DE. Convergence of integrin and growth factor receptor signaling pathways within the focal adhesion complex. Mol Biol Cell. 1995;6(10):1349-65.
54. Klint P, Kanda S, Kloog Y, Claesson-Welsh L. Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation. Oncogene. 1999;18(22):3354-64.
55. Hanks SK, Polte TR. Signaling through focal adhesion kinase. Bioessays. 1997;19(2):137-45.
56. Lepin EJ, Jin YP, Barwe SP, Rozengurt E, Reed EF. HLA class I signal transduction is dependent on Rho GTPase and ROK. Biochem Biophys Res Commun. 2004;323(1):213-7.
57. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926-45.
58. Thomas G. The S6 kinase signaling pathway in the control of development and growth. Biol Res. 2002;35(2):305-13.
59. Jin YP, Fishbein MC, Said JW, Jindra PT, Rajalingam R, Rozengurt E, Reed EF. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol. 2004;65(4):291-302.
60. Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol. 2004;34(8):2303-12.
61. Salama AD, Delikouras A, Pusey CD, Cook HT, Bhangal G, Lechler RI, Dorling A. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant. 2001;1(3):260-9.
62. Lepin EJ, Zhang Q, Zhang X, Jindra PT, Hong LS, Ayele P, Peralta MV, Gjertson DW, Kobashigawa JA, Wallace WD, Fishbein MC, Reed EF. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant. 2006;6(7):1560-71.
63. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110(2):177-89.
64. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110(2):163-75.
65. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14(14):1296-302.
66. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098- 101.
67. Yang Q, Inoki K, Ikenoue T, Guan KL. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 2006;20(20):2820-32.
68. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, Hara K, Tanaka N, Avruch J, Yonezawa K. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4EBP1 through their TOR signaling (TOS) motif. J Biol Chem. 2003;278(18):15461-4.
69. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003;17(7):1263-93.
70. Jindra PT, Jin YP, Jacamo R, Rozengurt E, Reed EF. MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway. Biochem Biophys Res Commun. 2008;369(2):781-7.
71. Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E, Edwards N, Oz M, Marks AR. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 2003;108(1):48-53.
72. Wilson SH, Ljubimov AV, Morla AO, Caballero S, Shaw LC, Spoerri PE, Tarnuzzer RW, Grant MB. Fibronectin fragments promote human retinal endothelial cell adhesion and proliferation and ERK activation through alpha5beta1 integrin and PI 3-kinase. Invest Ophthalmol Vis Sci. 2003;44(4):1704-15.
73. Sawhney RS, Cookson MM, Omar Y, Hauser J, Brattain MG. Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway. J Biol Chem. 2006;281(13):8497-510.
74. Vomastek T, Iwanicki MP, Schaeffer HJ, Tarcsafalvi A, Parsons JT, Weber MJ. RACK1 targets the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to link integrin engagement with focal adhesion disassembly and cell motility. Mol Cell Biol. 2007;27(23):8296-305.
75. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer. 2005;5(7):505-15.
76. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22(2):159-68.
77. Narayanan K, Jendrisak MD, Phelan DL, Mohanakumar T. HLA class I antibody mediated accommodation of endothelial cells via the activation of PI3K/cAMP dependent PKA pathway. Transpl Immunol. 2006;15(3):187-97.
78. Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell. 2002;13(7):2276-88.
79. Dormond O, Madsen JC, Briscoe DM. The effects of mTOR-Akt interactions on antiapoptotic signaling in vascular endothelial cells. J Biol Chem. 2007;282(32):23679-86.
80. Alexandre GP, Squifflet JP, De Bruyere M, Latinne D, Reding R, Gianello P, Carlier M, Pirson Y. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc. 1987;19(6):4538-42.
81. Bannett AD, McAlack RF, Raja R, Baquero A, Morris M. Experiences with known ABO-mismatched renal transplants. Transplant Proc. 1987;19(6):4543-6.
82. Starzl TE, Marchioro TL, Terasaki PI, Porter KA, Faris TD, Herrmann TJ, Vredevoe DL, Hutt MP, Ogden DA, Waddell WR. Chronic survival after human renal homotransplantation. Lymphocyte-antigen matching, pathology and influence of thymectomy. Ann Surg. 1965;162(4):749-87.
83. Murray JE, Gleason R, Bartholomay A. Third Report of the Human Kidney Transplant Registry. Transplantation. 1965;3:294-302.
84. Bannett AD, McAlack RF, Morris M, Chopek MW, Platt JL. ABO incompatible renal transplantation: a qualitative analysis of native endothelial tissue ABO antigens after transplantation. Transplant Proc. 1989;21(1 Pt 1):783-5.
85. Parker W, Lundberg-Swanson K, Holzknecht ZE, Lateef J, Washburn SA, Braedehoeft SJ, Platt JL. Isohemagglutinins and xenoreactive antibodies: members of a distinct family of natural antibodies. Hum Immunol. 1996;45(2):94-104.
86. Park WD, Grande JP, Ninova D, Nath KA, Platt JL, Gloor JM, Stegall MD. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant. 2003;3(8):952-60.
87. Stussi G, West L, Cooper DK, Seebach JD. ABO-incompatible allotransplantation as a basis for clinical xenotransplantation. Xenotransplantation. 2006;13(5):390-9.
88. Bach FH, Soares M, Lin Y, Ferran C. Barriers to xenotransplantation. Transplant Proc. 1999;31(4):1819-20.
89. Lesnikoski BA, Shaffer DA, Van der Werf WJ, Dalmasso AP, Soares MP, Latinne D, Bazin H, Hancock WW, Bach FH. Endothelial and host mononuclear cell activation and cytokine expression during rejection of pig-to-baboon discordant xenografts. Transplant Proc. 1995;27(1):290-1.
90. Blakely ML, Van der Werf WJ, Berndt MC, Dalmasso AP, Bach FH, Hancock WW. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation. 1994;58(10):1059-66.
91. Bach FH, Ferran C, Hechenleitner P, Mark W, Koyamada N, Miyatake T, Winkler H, Badrichani A, Candinas D, Hancock WW. Accommodation of vascularized xenografts: expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nat Med. 1997;3(2):196-204.
92. Leventhal JR, Matas AJ, Sun LH, Reif S, Bolman RM III, Dalmasso AP, Platt JL. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation. 1993;56(1):1-8.
93. Hancock WW, Blakely ML, Van der Werf W, Bach FH. Rejection of guinea pig cardiac xenografts post-cobra venom factor therapy is associated with infiltration by mononuclear cells secreting interferon-gamma and diffuse endothelial activation. Transplant Proc. 1993;25(5):2932.
94. Bach FH, Turman MA, Vercellotti GM, Platt JL, Dalmasso AP. Accommodation: a working paradigm for progressing toward clinical discordant xenografting. Transplant Proc. 1991;23(1 Pt 1):205-7.
95. Cozzi E, Bosio E, Seveso M, Vadori M, Ancona E. Xenotransplantation - current status and future perspectives. Br Med Bull. 2005;75-76, 99-114.
96. Zachary AA, Montgomery RA, Ratner LE, Samaniego-Picota M, Haas M, Kopchaliiska D, Leffell MS. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation. 2003;76(10):1519-25.
97. Zachary AA, Montgomery RA, Jordan SC, Reinsmoen NL, Claas FH, Reed EF. 14th International HLA and Immunogenetics Workshop: report on understanding antibodies in transplantation. Tissue Antigens. 2007;69 Suppl 1:160-73.
98. Pascual M, Saidman S, Tolkoff-Rubin N, Williams WW, Mauiyyedi S, Duan JM, Farrell ML, Colvin RB, Cosimi AB, Delmonico FL. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation. 1998;66(11):1460-4.
99. Reisaeter AV, Leivestad T, Albrechtsen D, Holdaas H, Hartmann A, Sodal G, Flatmark A, Fauchald P. Pretransplant plasma exchange or immunoadsorption facilitates renal transplantation in immunized patients. Transplantation. 1995;60(3):242-8.
100. Palmer A, Taube D, Welsh K, Bewick M, Gjorstrup P, Thick M. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet. 1989;1(8628):10-2.
101. Taube D, Palmer A, Welsh K, Bewick M, Snowden S, Thick M. Removal of anti-HLA antibodies prior to transplantation: an effective and successful strategy for highly sensitised renal allograft recipients. Transplant Proc. 1989;21(1 Pt 1):694-5.
102. Lynch RJ, Platt JL. Accommodation in organ transplantation. Curr Opin Organ Transplant. 2008;13(2):165-70.
103. Ulfvin A, Backer AE, Clausen H, Hakomori S, Rydberg L, Samuelsson BE, Breimer ME. Expression of glycolipid blood group antigens in single human kidneys: change in antigen expression of rejected ABO incompatible kidney grafts. Kidney Int. 1993;44(6):1289-97.
104. Yuzawa Y, Brett J, Fukatsu A, Matsuo S, Caldwell PR, Niesen N, Milgrom F, Godman G, Stern D, Andres G. Interaction of antibody with Forssman antigen in guinea pigs. A mechanism of adaptation to antibody- and complement-mediated injury. Am J Pathol. 1995;146(5):1260-72.
105. Siddiqui B, Hakomori S. A revised structure for the Forssman glycolipid hapten. J Biol Chem. 1971;246(18):5766-9.
106. Parker W, Holzknecht ZE, Song A, Blocher BA, Bustos M, Reissner KJ, Everett ML, Platt JL. Fate of antigen in xenotransplantation: implications for acute vascular rejection and accommodation. Am J Pathol. 1998;152(3):829-39.
107. Ding JW, Zhou T, Ma L, Yin D, Shen J, Ding CP, Tang IY, Byrne GW, Chong AS. Expression of complement regulatory proteins in accommodated xenografts induced by anti-alpha-Gal IgG1 in a rat-to-mouse model. Am J Transplant. 2008;8(1):32-40.
108. Lin SS, Hanaway MJ, Gonzalez-Stawinski GV, Lau CL, Parker W, Davis RD, Byrne GW, Diamond LE, Logan JS, Platt JL. The role of anti-Galalpha1-3Gal antibodies in acute vascular rejection and accommodation of xenografts. Transplantation. 2000;70(12):1667-74.
109. Lin SS, Weidner BC, Byrne GW, Diamond LE, Lawson JH, Hoopes CW, Daniels LJ, Daggett CW, Parker W, Harland RC, Davis RD, Bollinger RR, Logan JS, Platt JL. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest. 1998;101(8):1745-56.
110. Gloor JM, Lager DJ, Moore SB, Pineda AA, Fidler ME, Larson TS, Grande JP, Schwab TR, Griffin MD, Prieto M, Nyberg SL, Velosa JA, Textor SC, Platt JL, Stegall MD. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation. 2003;75(7):971-7.
111. Parker W, Saadi S, Lin SS, Holzknecht ZE, Bustos M, Platt JL. Transplantation of discordant xenografts: a challenge revisited. Immunol Today. 1996;17(8):373-8.
112. Platt JL, Lindman BJ, Geller RL, Noreen HJ, Swanson JL, Dalmasso AP, Bach FH. The role of natural antibodies in the activation of xenogenic endothelial cells. Transplantation. 1991;52(6):1037-43.
113. Yu PB, Holzknecht ZE, Bruno D, Parker W, Platt JL. Modulation of natural IgM binding and complement activation by natural IgG antibodies: a role for IgG anti-Gal alpha1-3Gal antibodies. J Immunol. 1996;157(11):5163-8.
114. Mohiuddin MM, Ogawa H, Yin DP, Shen J, Galili U. Antibody-mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen. Transplantation. 2003;75(3):258-62.
115. Yu PB, Parker W, Nayak JV, Platt JL. Sensitization with xenogeneic tissues alters the heavy chain repertoire of human anti-Galalpha1-3Gal antibodies. Transplantation. 2005;80(1):102-9.
116. Platt JL, Vercellotti GM, Lindman BJ, Oegema TR Jr, Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med. 1990;171(4):1363-8.
117. Dalmasso AP, Vercellotti GM, Fischel RJ, Bolman RM, Bach FH, Platt JL. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol. 1992;140(5):1157-66.
118. Dalmasso AP, Benson BA, Johnson JS, Lancto C, Abrahamsen MS. Resistance against the membrane attack complex of complement induced in porcine endothelial cells with a Gal alpha(1-3)Gal binding lectin: up-regulation of CD59 expression. J Immunol. 2000;164(7):3764-73.
119. Oldham ER, Velardo MA, Platt JL, Logan JS, Diamond L. High-level tissue specific expression of human CD59, MCP, and DAF proteins from genomic clones in transgenic mice. Transplant Proc. 1996;28(2):693.
120. Grubbs BC, Benson BA, Dalmasso AP. Characteristics of CD59 up-regulation induced in porcine endothelial cells by alphaGal ligation and its association with protection from complement. Xenotransplantation. 2003;10(5):387-97.
121. Suhr BD, Black SM, Guzman-Paz M, Matas AJ, Dalmasso AP. Inhibition of the membrane attack complex of complement for induction of accommodation in the hamster-to-rat heart transplant model. Xenotransplantation. 2007;14(6):572-9.
122. Diamond LE, McCurry KR, Martin MJ, McClellan SB, Oldham ER, Platt JL, Logan JS. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation. 1996;61(8):1241-9.
123. Grehan JF, Levay-Young BK, Fogelson JL, Francois-Bongarcon V, Benson BA, Dalmasso AP. IL-4 and IL-13 induce protection of porcine endothelial cells from killing by human complement and from apoptosis through activation of a phosphatidylinositide 3-kinase/Akt pathway. J Immunol. 2005;175(3):1903-10.
124. Black SM, Grehan JF, Rivard AL, Benson BA, Wahner AE, Koch AE, Levay-Young BK, Dalmasso AP. Porcine endothelial cells and iliac arteries transduced with AdenoIL-4 are intrinsically protected, through Akt activation, against immediate injury caused by human complement. J Immunol. 2006;177(10):7355-63.
125. Black SM, Schott ME, Benson BA, Rutherford MS, Young BK, Dalmasso AP. Interleukin-4 induces lipogenesis in porcine endothelial cells, which in turn is critical for induction of protection against complement-mediated injury. Transplant Proc. 2008;40(2):638-40.
126. Zhai Y, Shen XD, Gao F, Coito AJ, Wasowska BA, Salama A, Schmitt I, Busuttil RW, Sayegh MH, Kupiec-Weglinski JW. The CD154-CD40 T cell costimulation pathway is required for host sensitization of CD8(+) T cells by skin grafts via direct antigen presentation. J Immunol. 2002;169(3):1270-6.
127. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol. 2002;13(2):559-75.
128. Jain A, Atkinson TP, Lipsky PE, Slater JE, Nelson DL, Strober W. Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. J Clin Invest. 1999;103(8):1151-8.
129. Zhai Y, Kupiec-Weglinski JW. The CD154-CD40 costimulation pathway in organ transplantation. Transplant Rev. 2004;18(1):10-9.
130. Tanemura M, Yin D, Chong AS, Galili U. Differential immune responses to alpha-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. J Clin Invest. 2000;105(3):301-10.
131. Lin Y, Soares MP, Sato K, Csizmadia E, Robson SC, Smith N, Bach FH. Long-term survival of hamster hearts in presensitized rats. J Immunol. 2000;164(9):4883-92.
132. Wang N, Lee JM, Soares MP, Csizmadia E, Robson SC, Smith N, Bach FH, Lin Y. Long-term survival of hamster hearts in presensitized rats. Transplant Proc. 2001;33(1-2):747-8.
133. Nath KA, Balla G, Vercellotti GM, Balla J, Jacob HS, Levitt MD, Rosenberg ME. Induction of heme oxygenase is a rapid, protective response in rhabdomyoly-sis in the rat. J Clin Invest. 1992;90(1):267-70.
134. Soares MP, Lin Y, Anrather J, Csizmadia E, Takigami K, Sato K, Grey ST, Colvin RB, Choi AM, Poss KD, Bach FH. Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med. 1998;4(9):1073-7.
135. Tabata T, de Perrot M, Keshavjee S, Liu M, Downey GP, Waddell TK. Accommodation after lung xenografting from hamster to rat. Transplantation. 2003;75(5):607-12.
136. Semiltova N, Shen XD, Fishbein MC, Gao F, Slomowitz SJ, Jiao Q, Mukherjee K, Busuttil RW, Kupiec-Weglinski JW, Ghobrial RM. Posttransplant administration of allochimeric major histocompatibility complex class-I-molecules induces true transplantation tolerance. Transplantation. 2003;75(4):550-3.
137. Singer JS, Mhoyan A, Fishbein MC, Shen XD, Gao F, Zhao D, Coito AJ, Reemtsen BL, Amersi F, Busuttil RW, Kupiec-Weglinski JW, Ghobrial RM. Allochimeric class I MHC molecules prevent chronic rejection and attenuate alloantibody responses. Transplantation. 2001;72(8):1408-16.
138. Semiletova NV, Shen XD, Baibakov B, Feldman DM, Mukherjee K, Frank JM, Stepkowski SM, Busuttil RW, Kupiec-Weglinski JW, Ghobrial RM. Inhibition of chronic rejection by antibody induced vascular accommodation in fully allogeneic heart allografts. Transplantation. 2005;80(11):1535-40.
139. Chiffoleau E, Beriou G, Dutartre P, Usal C, Soulillou JP, Cuturi MC. Induction of donorspecific allograft tolerance by short-term treatment with LF15-0195 after transplantation. Evidence for a direct effect on T-cell differentiation. Am J Transplant. 2002;2(8):745-57.
140. Takeuchi I, Chikaraishi T, Seki T, Kanagawa K, Koyanagi T. Immunological analysis of rat renal transplant recipients exhibiting long-term survival following treatment with 15-deoxyspergualin in the early postoperative phase. Int J Urol. 1998;5(5):476-81.
141. Fujii H, Takada T, Nemoto K, Yamashita T, Abe F, Fujii A, Takeuchi T. Deoxyspergualin directly suppresses antibody formation in vivo and in vitro. J Antibiot (Tokyo). 1990;43(2):213-9.
142. Tepper MA, Nadler SG, Esselstyn JM, Sterbenz KG. Deoxyspergualin inhibits kappa light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-kappa B activation. J Immunol. 1995;155(5):2427-36.
143. Heslan JM, Renaudin K, Thebault P, Josien R, Cuturi MC, Chiffoleau E. New evidence for a role of allograft accommodation in long-term tolerance. Transplantation. 2006;82(9):1185-93.
144. Jindra PT, Hsueh A, Hong L, Gjertson D, Shen XD, Gao F, Dang J, Mischel PS, Baldwin WM III, Fishbein MC, Kupiec-Weglinski JW, Reed EF. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol. 2008;180(4):2214-24.
145. Snanoudj R, Beaudreuil S, Arzouk N, de Preneuf H, Durrbach A, Charpentier B. Immunological strategies targeting B cells in organ grafting. Transplantation. 2005;79(3 Suppl):S33-6.
146. Hancock WW, Buelow R, Sayegh MH, Turka LA. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med. 1998;4(12):1392-6.
147. Willis D, Moore AR, Frederick R, Willoughby DA. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat Med. 1996;2(1):87-90.
148. Vogt BA, Alam J, Croatt AJ, Vercellotti GM, Nath KA. Acquired resistance to acute oxidative stress. Possible role of heme oxygenase and ferritin. Lab Invest. 1995;72(4):474-83.
149. Murry C, Jennings R, Reimer K. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124-36.
150. Huang Y, Shan J, Wang C, Ma J, Li D, Li L, Li S, Li Y. Can ischemic preconditioning alone really protect organs from ischemia reperfusion injury in transplantation. Transpl Immunol. 2009;20(3):127-31.
151. Koch CA, Kanazawa A, Nishitai R, Knudsen BE, Ogata K, Plummer TB, Butters K, Platt JL. Intrinsic resistance of hepatocytes to complement-mediated injury. J Immunol. 2005;174(11):7302-9.
152. Platt JL, Nath KA. Heme oxygenase: protective gene or Trojan horse. Nat Med. 1998;4(12):1364-5.
153. Otterbein LE, Soares MP, Yamashita K, Bach FH. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. 2003;24(8):449-55.
154. Racanelli V, Rehermann B. Hepatitis C virus infection: when silence is deception. Trends Immunol. 2003;24(8):456-64.
155. Xu XN, Screaton GR, McMichael AJ. Virus infections: escape, resistance, and counterattack. Immunity. 2001;15(6):867-70.
156. Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev. 2000;26(4):269-86.
157. Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol. 2003;131(2):254-63.
158. Platt JL. C4d and the fate of organ allografts. J Am Soc Nephrol. 2002;13(9):2417-9.
159. Smith RN, Kawai T, Boskovic S, Nadazdin O, Sachs DH, Cosimi AB, Colvin RB. Chronic antibody mediated rejection of renal allografts: pathological, serological and immunologic features in nonhuman primates. Am J Transplant. 2006;6(8):1790-8.
160. Smith RN, Kawai T, Boskovic S, Nadazdin O, Sachs DH, Cosimi AB, Colvin RB. Four stages and lack of stable accommodation in chronic alloantibody- mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant. 2008;8(8):1662-72.
161. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753-60.
162. Woodruff MF, Simpson LO. Experimental skin grafting in rats; with special reference to split skin grafts. Plast Reconstr Surg (1946). 1955;15(6):451-8.
163. Parker W, Lin SS, Platt JL. Antigen expression in xeno-transplantation: how low must it go? Transplantation. 2001;71(2):313-9.
164. McCurry KR, Parker W, Cotterell AH, Weidner BC, Lin SS, Daniels LJ, Holzknecht ZE, Byrne GW, Diamond LE, Logan JS, Platt JL. Humoral responses to pig-to-baboon cardiac transplantation: implications for the pathogenesis and treatment of acute vascular rejection and for accommodation. Hum Immunol. 1997;58(2):91-105.
165. Adeyi OA, Girnita AL, Howe J, Marrari M, Awadalla Y, Askar M, Martell J, Zeevi A, Shapiro R, Nalesnik M, Randhawa P, Demetris AJ, Duquesnoy RJ. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol. 2005;14(1):53-62.